Production (Stage)
Neuphoria Therapeutics Inc.
NEUP
$6.87
-$0.28-3.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 11.26M | -1.94M | -804.80K | -2.62M | -2.78M |
| Total Depreciation and Amortization | 165.40K | 166.10K | 165.70K | 331.50K | 165.70K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 668.40K | -1.25M | -2.60M | -1.01M | 423.20K |
| Change in Net Operating Assets | -642.50K | -328.20K | -1.20M | 727.40K | -1.11M |
| Cash from Operations | 11.45M | -3.36M | -4.43M | -2.57M | -3.30M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -71.30K | -- |
| Cash from Investing | -- | -- | -- | -71.30K | -- |
| Total Debt Issued | -- | -- | -- | -380.90K | -- |
| Total Debt Repaid | -- | -- | -- | 28.30K | -- |
| Issuance of Common Stock | 1.22M | -- | 400.00 | 1.40M | 2.34M |
| Repurchase of Common Stock | -- | -400.00 | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -61.10K | -111.20K | -227.70K | 2.81M | -588.60K |
| Cash from Financing | 1.16M | -111.60K | -227.30K | 3.86M | 1.75M |
| Foreign Exchange rate Adjustments | 85.00K | -276.70K | 138.40K | 161.30K | -185.90K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 12.70M | -3.75M | -4.52M | 1.38M | -1.73M |